Could fecal microbiota transplantation help patients heal after stem cell transplantation?
A new study published in Nature Communications
shows that oral fecal microbiota transplantation (FMT) is a safe
addition to preventing graft-versus-host disease in patients undergoing
stem cell transplantation for blood cancers. This research is part of a
phase 2 clinical trial led by Armin Rashidi, MD, PhD,
a medical oncologist at Fred Hutch.
The randomized phase of the trial will study whether FMT improves health outcomes for patients undergoing stem cell transplantation, such as less acute graft-versus-host disease, fewer hospitalizations, fewer infections, better quality of life and longer survival.
Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)
No comments:
Post a Comment
Pharmaceutical Microbiology Resources